Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal oxytocin crossover study in youth with autism spectrum disorder
2021-006531-26Phase 2Active
- Sponsor
- Oslo University Hospital
- Start
- Nov 2022
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of oxytocin in Autism Spectrum Disorder (ASD) (2 arms), sponsored by Oslo University Hospital. Primary endpoints: Social behavior and Repetitive behavior. Started Nov 2022; status: active.
02
Drugs
oxytocin
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on 2021-006531-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-006531-26.